CA
Therapeutic Areas
Lexicon Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INPEFA (sotagliflozin) | Heart Failure | Approved |
| LX9211 | Diabetic Peripheral Neuropathic Pain (DPNP) | Phase 2 |
Leadership Team at Lexicon Pharmaceuticals
LC
Lonnel Coats
Chief Executive Officer
JL
Jeffrey L. Wade
President, Chief Financial Officer & Corporate Secretary
AJ
Alan J. Main, Ph.D.
Executive Vice President, Research & Development and Chief Scientific Officer
BT
Brian T. Crum
Senior Vice President, Corporate Affairs & Investor Relations
AM
Arthur M. Pappas
Chairman of the Board of Directors
DL
David L. Southwell
Director
JF
John F. Kouten
Director
KA
Keith A. Sutton
Director
HP
H. Paul Dorman
Director
WJ
W. James O'Shea
Director